Mutations in the genes such as nucleophosmin-1 (NPM1), FMS-related tyrosine kinase 3 (FLT3), and CCAAT/enhancer-binding protein alpha (CEBPA) in cytogenetically normal AML influence the prognosis of AML patients [12] and have entered clinical routine [11, 13]. The gene discussed is CEBPA; the disease is acute myeloid leukemia.